AMPH

23.63

5.37% -1.34

Handel nachbörslich: 23.63

Amphastar Pharmaceuticals Inc (AMPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt AMPH? Forum Prognose

Schlusskurs vom Vortag:

$24.97

Offen:

$25.01

24-Stunden-Volumen:

607.45K

Relative Volume:

1.22

Marktkapitalisierung:

$1.10B

Einnahmen:

$722.68M

Nettoeinkommen (Verlust:

$134.71M

KGV:

8.8502

EPS:

2.67

Netto-Cashflow:

$109.94M

1W Leistung:

-11.66%

1M Leistung:

-16.80%

6M Leistung:

+0.47%

1J Leistung:

-48.95%

1-Tages-Spanne:

$23.20

$25.02

1-Wochen-Bereich:

$23.20

$27.07

52-Wochen-Spanne:

$20.39

$53.95

Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile

Firmenname

Amphastar Pharmaceuticals Inc

Sektor

Healthcare (1141)

Branche

Drug Manufacturers - Specialty & Generic (83)

Telefon

909-980-9484

Adresse

11570 SIXTH STREET, RANCHO CUCAMONGA, CA

Mitarbeiter

2,028

Twitter

Nächster Verdiensttermin

2024-12-06

Neueste SEC-Einreichungen

AMPH's Discussions on Twitter

Vergleichen Sie AMPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AMPH Amphastar Pharmaceuticals Inc	23.63	1.16B	722.68M	134.71M	109.94M	2.67
ZTS Zoetis Inc	141.11	63.55B	9.39B	2.62B	2.22B	5.8121
TAK Takeda Pharmaceutical Co Adr	13.71	44.47B	29.96B	957.25M	4.77B	0.2956
HLN Haleon Plc Adr	9.00	40.17B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	20.03	22.99B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	440.00	20.14B	3.08B	1.24B	1.07B	25.61

Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-12	Hochstufung	Needham	Hold → Buy
2025-05-12	Herabstufung	JP Morgan	Overweight → Neutral
2025-02-04	Herabstufung	Piper Sandler	Overweight → Neutral
2024-11-22	Eingeleitet	Wells Fargo	Equal Weight
2024-03-05	Eingeleitet	JP Morgan	Overweight
2023-11-17	Eingeleitet	BofA Securities	Neutral
2023-07-25	Fortgesetzt	Jefferies	Buy
2022-10-21	Fortgesetzt	Jefferies	Buy
2022-07-29	Eingeleitet	CapitalOne	Overweight
2022-01-07	Hochstufung	Piper Sandler	Neutral → Overweight
2021-01-08	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-10-05	Hochstufung	Northland Capital	Market Perform → Outperform
2020-05-01	Eingeleitet	Northland Capital	Outperform
2019-03-13	Herabstufung	Needham	Buy → Hold
2019-03-13	Herabstufung	Piper Jaffray	Overweight → Neutral
2018-08-10	Bestätigt	Needham	Buy
2018-03-13	Bestätigt	Needham	Buy
2017-12-01	Bestätigt	Needham	Buy
2017-11-09	Herabstufung	Raymond James	Outperform → Mkt Perform
2017-09-27	Bestätigt	Needham	Buy
2017-03-14	Herabstufung	Raymond James	Strong Buy → Outperform
2016-08-09	Bestätigt	Needham	Buy
2016-05-10	Bestätigt	Needham	Buy
2016-02-19	Eingeleitet	Wells Fargo	Outperform
2015-06-19	Bestätigt	Needham	Buy
2015-06-03	Eingeleitet	Raymond James	Strong Buy
2014-07-21	Eingeleitet	Needham	Buy

Alle ansehen

Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten

09:54 AM

Will Amphastar Pharmaceuticals Inc. (29A) stock gain from lower interest ratesJuly 2025 Setups & Entry and Exit Point Strategies - newser.com

09:54 AM

Oct 09, 2025

BofA Cuts Price Target on Amphastar Pharmaceuticals to $31 From $32 - MarketScreener

Oct 09, 2025

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga

Oct 09, 2025

Can Amphastar Pharmaceuticals Inc. stock attract ESG capital inflowsMarket Volume Report & Daily Entry Point Trade Alerts - newser.com

Oct 09, 2025

How to monitor Amphastar Pharmaceuticals Inc. with trend dashboardsQuarterly Risk Review & Safe Capital Growth Trade Ideas - newser.com

Oct 09, 2025

Will Amphastar Pharmaceuticals Inc. stock recover after recent dropMarket Volume Summary & Expert Curated Trade Setups - newser.com

Oct 09, 2025

Oct 08, 2025

Amphastar Pharmaceuticals' (AMPH) Hold (C-) Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 08, 2025

Oct 06, 2025

Will Amphastar Pharmaceuticals Inc. (29A) stock return to pre crash levels2025 Volume Leaders & Growth Focused Entry Reports - newser.com

Oct 06, 2025

Oct 05, 2025

What analysts say about Cochlear Limited OC5 stockIPO Market Watch & Zero-Cost Stock Research by Professionals - earlytimes.in

Oct 05, 2025

Momentum divergence signals in Amphastar Pharmaceuticals Inc. chartAnalyst Downgrade & Precise Swing Trade Entry Alerts - newser.com

Oct 05, 2025

Why Amphastar Pharmaceuticals Inc. stock is a value investor pickJuly 2025 Patterns & Reliable Momentum Entry Alerts - newser.com

Oct 05, 2025

Oct 04, 2025

Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference - 富途牛牛

Oct 04, 2025

Oct 03, 2025

Will Amphastar Pharmaceuticals Inc. (29A) stock beat international competitionEarnings Recap Report & Free High Return Stock Watch Alerts - newser.com

Oct 03, 2025

Is Amphastar Pharmaceuticals Inc. (29A) stock cheap vs fundamentalsEarnings Trend Report & Expert Approved Momentum Ideas - newser.com

Oct 03, 2025

Does Amphastar Pharmaceuticals Inc. stock trade at a discount to peersMarket Growth Review & Low Drawdown Investment Ideas - newser.com

Oct 03, 2025

Oct 02, 2025

Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells 500 Shares - MarketBeat

Oct 02, 2025

What drives Amphastar Pharmaceuticals Inc 29A stock pricePrice Support Zones & Free Get High Impact Recommendations - earlytimes.in

Oct 02, 2025

Sep 30, 2025